Top

Published in:

Open Access 01-12-2010 | Minireview

Advances in drug therapy for systemic lupus erythematosus

Author: Daniel J Wallace

Published in: BMC Medicine | Issue 1/2010

Abstract

Systemic lupus erythematosus (SLE) is an autoimmune disorder that afflicts 500,000 people in the United States. There has not been a new SLE drug approved in the United States since 1958. However, a guidance document issued by the Food and Drug Administration in 2005 provided a roadmap for investigators which spawned numerous ongoing clinical trials. Among these, Belimumab, a monoclonal antibody to soluble B lymphocyte stimulator, met its primary endpoints in two large trials and will probably obtain FDA approval soon. Other promising agents targeting a variety of mechanisms of action are currently in development. This minireview highlights the latest therapies under investigation in SLE and gives an overview of the pathways that are specifically being targeted.

Available only for authorised users

Wallace DJ, Hahn BH, (Eds): Dubois' Lupus Erythematosus. 2007, Philadelphia: Lippincott Williams & Wilkins, 7

Decker JL, Steinberg AD, Reinertsen JL, Plotz PH, Balow JE, Klippel JH: NIH conference: systemic lupus erythematosus: evolving concepts. Ann Intern Med. 1979, 91: 587-604.CrossRefPubMed

U.S. Food and Drug Administration: Guidance for Industry on Systemic Lupus Erythematosus: Developing Drugs for Treatment. Accessed July 28, 2010. Also available at Federal Register 70(59):15868, March 29, 2005, [http://www.fda.gov/ohrms/dockets/dockets/05d01-6/05d0106.htm]

U.S. Food and Drug Administration: Guidance for Industry on Systemic Lupus Erythematosus: Developing Medical Products for Treatment. Accessed July 28, 2010, [http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm]

Yee CS, Farewell V, Isenberg DA, Prabu A, Sokoll K, Teh LS, Rahman A, Bruce IN, Griffiths B, Akil M, McHugh N, D'Cruz D, Khamashta MA, Bowman S, Maddison P, Zoma A, Allen E, Gordon C, British Isles Lupus Assessment Group: Revised British Isles Lupus Assessment Group 2004 index: a reliable tool for assessment of systemic lupus erythematosus activity. Arthritis Rheum. 2006, 54: 3300-3305. 10.1002/art.22162.CrossRefPubMed

Wright SA, O'Prey FM, McHenry MT, Leahey WJ, Devine AB, Duffy EM, Johnston DG, Finch MB, Bell AL, McVeigh GE: A randomised interventional trial of omega-3-polyunsaturated fatty acids on endothelial function and disease activity in systemic lupus erythematosus. Ann Rheum Dis. 2008, 67: 841-848. 10.1136/ard.2007.077156.CrossRefPubMed

Fortin PR, Abrahamowicz M, Ferland D, Lacaille D, Smith CD, Zummer M, Canadian Network for Improved Outcomes in Systemic Lupus: Steroid-sparing effects of methotrexate in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2008, 59: 1796-1804. 10.1002/art.24068.CrossRefPubMed

Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D, Li LS, Mysler E, Sánchez-Guerrero J, Solomons N, Wofsy D, Aspreva Lupus Management Study Group: Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol. 2009, 20: 1103-1112. 10.1681/ASN.2008101028.CrossRefPubMedPubMedCentral

Wofsy D, Appel GB, Dooley MA, Ginzler EM, Isenberg D, Jayne D, Solomons N, Lisk L: Aspreva Lupus Management Study maintenance results. Lupus. 2010, 19 (Suppl): 27..

10.

Lampropoulos CE, D'Cruz DP: Topical calcineurin inhibitors in systemic lupus erythematosus. Ther Clin Risk Manag. 2010, 6: 95-101. 10.2147/TCRM.S3193.CrossRefPubMedPubMedCentral

11.

Remer CF, Weisman MH, Wallace DJ: Benefits of leflunomide in systemic lupus erythematosus: a pilot observational study. Lupus. 2001, 10: 480-483. 10.1191/096120301678416033.CrossRefPubMed

12.

Sánchez-Guerrero J, Fragoso-Loyo HE, Neuwelt CM, Wallace DJ, Ginzler EM, Sherrer YR, McIlwain HH, Freeman PG, Aranow C, Petri MA, Deodhar AA, Blanton E, Manzi S, Kavanaugh A, Lisse JR, Ramsey-Goldman R, McKay JD, Kivitz AJ, Mease PJ, Winkler AE, Kahl LE, Lee AH, Furie RA, Strand CV, Lou L, Ahmed M, Quarles B, Schwartz KE: Effects of prasterone on bone mineral density in women with active systemic lupus erythematosus receiving chronic glucocorticoid therapy. J Rheumatol. 2008, 35: 1567-1575.PubMed

13.

Merrill JT, Burgos-Varagas R, Westhovens R, Chalmers A, D'Cruz D, Wallace DJ, Bae SC, Sigal L, Becker JC, Raphupathi K, Peng LT, Kinasczuk M, Nash P: The efficacy and safety of abatacept in patients with non-life-threatening manifestations of SLE: results of a 12-month exploratory study. Arthritis Rheum. 2010, 62: 377-387.

14.

Boumpas DR, Furie R, Manzi S, Ilei GG, Wallace DJ, Balow JE, Vaishnaw A: A short course of BG9588 (anti-CD 40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum. 2003, 48: 719-727. 10.1002/art.10856.CrossRefPubMed

15.

Kalunian KC, Davis JC, Merrill JT, Totoritis MC, Wofsy D, IDEC-131 Lupus Study Group: Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2002, 46: 3251-3258. 10.1002/art.10681.CrossRefPubMed

16.

Czeloth N, Dalken B, Engling A, Osterroth F, Aigner S, Abufarag A, Wartenberg-Demand A, Koch H, Becker C, Jonuleit H, Daniel V, Haefeli WE, Schwarz A, Hass J, Wildemann B, Uherek C: Selective activation of naturally occurring T cells (Tregs) by the monoclonal antibody BT-061 as a novel therapeutic opportunity: preclinical and early clinical results. Annals Rheum Dis. 2010, 69 (S1): 99.

17.

Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC, Utset TO, Gordon C, Isenberg DA, Hsieh HJ, Zhang D, Brunetta PG: Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus. Arthritis Rheum. 2010, 62: 222-233. 10.1002/art.27233.CrossRefPubMedPubMedCentral

18.

Furie R, Looney RJ, Rovin B, Latinis KM, Appel G, Sanchez-Guerrero J, Fervenza FC, Maciuca R, Brunetta P, Zhang D, Garg J: Efficacy and safety of rituximab in subjects with active proliferative lupus nephritis (LN): results from the randomized, double-blind phase III LUNAR study. Arthritis Rheum. 2009, 60: S429.

19.

Wallace D, Kalunian K, Petri M, Strand V, Kilgallen B, Barry A, Gordon C: Epratuzumab demonstrates clinically meaningful improvements in patients with moderate to severe systemic lupus erythematosus (SLE): results from EMBLEM, a phase IIb study. Annals Rheum Dis. 2010, 69 (Suppl 3): 558.

20.

Wallace DJ, Stohl W, Furie RA, Lisse JR, Mc Kay JD, Merrill JT, Petri MA, Ginzler EM, Chatham WW, McCune WJ, Fernandez V, Chevrier MR, Zhong ZJ, Freimuth WW: A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum. 2009, 61: 1168-1178. 10.1002/art.24699.CrossRefPubMedPubMedCentral

21.

Navarra S, Ilianova E, Bae SC, Guzman R, Tanasescu C, Gallacher A, Levy RA, Li EK, Thomas M, Jimenez R, Leon M, Hall S, Lan J, Kim HY, Pineda L, Zhong Z, Freimuth W, Petri M, BLISS-52 Study Group: Belimumab, a BlyS-specific inhibitor reduced disease activity, flares and steroid use in patients with seropositive systemic lupus erythematosus (SLE): BLISS-52 study. Annals Rheum Dis. 2010, 69 (S1).

22.

Furie RA, Gladman D, d'Cruz D, Zamani O, Wallace D, von Vollenhoven R, Tegzova D, Merrill JT, Schwarting A, Clarke AE, Doria AE, Sanchez-Guerrero J, Chatham WW, Manzi S, Ginzler E, Mc Kay J, Stohl W, Zhong ZJ, Hough D, Cooper SM, Freimuth W, Petri M, Belimumab : A BLyS specific inhibitor, reduced disease activity and severe flares with seropositive SLE: BLISS-76 study. Lupus. 2010, 19S: 13.

23.

Aringer M, Houssiau F, Gordon C, Graninger WB, Voll RE, Rath E, Steiner G, Smolen JS: Adverse events and efficacy of TNF-α blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients. Rheumatology (Oxford). 2009, 48: 1451-1454. 10.1093/rheumatology/kep270.CrossRef

24.

Illei GG, Shirota Y, Yarboro CH, Daruwalla J, Tackey E, Takada K, Fleisher T, Balow JE, Lipsky PE: Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum. 2010, 62: 542-552. 10.1002/art.27221.CrossRefPubMedPubMedCentral

25.

Cardiel MH, Tumlin JA, Furie RA, Wallace DJ, Joh T, Linnik MD, LJP 394-90-09 Investigator Consortium: Abetimus sodium for renal flare in systemic lupus erythematosus: results of a randomized, controlled phase III trial. Arthritis Rheum. 2008, 58: 2470-2480. 10.1002/art.23673.CrossRefPubMed

26.

Teva Pharmaceutical Industries Ltd.: Press release September 19, 2007. Accessed July 28, 2010, [http://www.tevapharm.com/pr/2007/pr_689.asp]

27.

Weinblatt M, Kavanaugh A, Genovese M, Grossbard E, Magilavy D: Treatment of rheumatoid arthritis (RA) with an oral syk kinase inhibitor: A 6 month randomized placebo controlled phase 2b study in patients with active RA on chronic methotrexate. American College of Rheumatology. 2009, Accessed November 17, 2010, [http://acr.confex.com/acr/2009/webprogram/Paper17160.html] annual scientific meeting, Abstract LB2

28.

Kaplan M: Eculizumab (Alexion). Curr Opin Investig Drugs. 2002, 3: 1017-1023.PubMed

29.

Wallace DJ, Petri M, Olsen N, Kyriou K, Dennis G, Yao Y, Jallal B, Coyle A, Zeng L, White B: MEDI-545, an anti-interferon α monoclonal antibody, shows evidence of clinical activity in systemic lupus erythematosus. Arthritis Rheum. 2007, 56: S526.

30.

Mc Bride J, Wallace DJ, Morimoto AY, Zhenling Y, Abbas A, Romeo M, Jiang J, Drappa J: Safety and pharmacodyamic response with administration of single and repeat doses of rontiluzmab in a phase I, placebo, controlled, double-blind, dose escalation study in SLE. Lupus. 2010, 19S: 15.

The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1741-7015/8/77/prepub

Title: Advances in drug therapy for systemic lupus erythematosus
Author: Daniel J Wallace
Publication date: 01-12-2010
Publisher: BioMed Central
Published in: BMC Medicine / Issue 1/2010
Electronic ISSN: 1741-7015
DOI: https://doi.org/10.1186/1741-7015-8-77

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Advances in drug therapy for systemic lupus erythematosus

Abstract

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2010

Internet addiction: a 21stcentury epidemic?

An evaluation of inflammatory gene polymorphisms in sibships discordant for premature coronary artery disease: the GRACE-IMMUNE study

Normalisation process theory: a framework for developing, evaluating and implementing complex interventions

The impact of herpes zoster and post-herpetic neuralgia on quality-of-life

Analysis of sex and gender-specific research reveals a common increase in publications and marked differences between disciplines

Routine resite of peripheral intravenous devices every 3 days did not reduce complications compared with clinically indicated resite: a randomised controlled trial